Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation.
In this paper, we investigate the pharmacokinetics and effect of doxorubicin and cisplatin in vascularized tumors through two-dimensional simulations. We take into account especially vascular and morphological heterogeneity as well as cellular and lesion-level pharmacokinetic determinants like P-glycoprotein (Pgp) efflux and cell density. To do this we construct a multi-compartment PKPD model calibrated from published experimental data and simulate 2-h bolus administrations followed by 18-h drug washout. Our results show that lesion-scale drug and nutrient distribution may significantly impact therapeutic efficacy and should be considered as carefully as genetic determinants modulating, for example, the production of multidrug-resistance protein or topoisomerase II. We visualize and rigorously quantify distributions of nutrient, drug, and resulting cell inhibition. A main result is the existence of significant heterogeneity in all three, yielding poor inhibition in a large fraction of the lesion, and commensurately increased serum drug concentration necessary for an average 50% inhibition throughout the lesion (the IC(50) concentration). For doxorubicin the effect of hypoxia and hypoglycemia ("nutrient effect") is isolated and shown to further increase cell inhibition heterogeneity and double the IC(50), both undesirable. We also show how the therapeutic effectiveness of doxorubicin penetration therapy depends upon other determinants affecting drug distribution, such as cellular efflux and density, offering some insight into the conditions under which otherwise promising therapies may fail and, more importantly, when they will succeed. Cisplatin is used as a contrast to doxorubicin since both published experimental data and our simulations indicate its lesion distribution is more uniform than that of doxorubicin. Because of this some of the complexity in predicting its therapeutic efficacy is mitigated. Using this advantage, we show results suggesting that in vitro monolayer assays using this drug may more accurately predict in vivo performance than for drugs like doxorubicin. The nonlinear interaction among various determinants representing cell and lesion phenotype as well as therapeutic strategies is a unifying theme of our results. Throughout it can be appreciated that macroscopic environmental conditions, notably drug and nutrient distributions, give rise to considerable variation in lesion response, hence clinical resistance. Moreover, the synergy or antagonism of combined therapeutic strategies depends heavily upon this environment.
Sinek
John P
JP
Department of Mathematics, University of California, Irvine, CA, USA.
Sanga
Sandeep
S
Zheng
Xiaoming
X
Frieboes
Hermann B
HB
Ferrari
Mauro
M
Cristini
Vittorio
V
D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000493:pharmacokinetics / Q000494:pharmacology; D003198:Computer Simulation; D004273:DNA, Neoplasm / Q000378:metabolism; D004317:Doxorubicin / Q000493:pharmacokinetics / Q000494:pharmacology; D005260:Female; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000378:metabolism
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D004317:Doxorubicin; D002945:Cisplatin
Int J Cancer. 2000 Apr 1;86(1):101-7
10728602
Neuroimage. 2007;37 Suppl 1:S59-70
17475515
Clin Cancer Res. 1999 Jul;5(7):1703-7
10430072
Biophys J. 2005 Dec;89(6):3884-94
16199495
Cancer Chemother Pharmacol. 1991;27(6):417-22
2013111
J Theor Biol. 2003 Jan 21;220(2):201-13
12468292
Cancer Res. 2001 Sep 15;61(18):6624-8
11559524
Cytometry. 1995 Aug 1;20(4):307-14
7587718
Recent Results Cancer Res. 1984;95:134-49
6396756
Endocr Relat Cancer. 2002 Sep;9(3):171-82
12237245
J Cancer Res Clin Oncol. 1994;120(5):293-7
8126058
Blood. 1997 May 15;89(10):3745-54
9160680
J Mol Biol. 1974 Jun 25;86(2):469-89
4416620
Drug Metab Dispos. 2002 Feb;30(2):183-90
11792689
Nat Rev Cancer. 2006 Aug;6(8):583-92
16862189
Expert Rev Anticancer Ther. 2006 Oct;6(10):1361-76
17069522
Cancer Res. 2006 Feb 1;66(3):1597-604
16452218
Bull Math Biol. 2004 Sep;66(5):1039-91
15294418
Cancer Res. 1984 Jan;44(1):238-44
6197161
Bull Math Biol. 2003 Jul;65(4):609-40
12875336
Bull Math Biol. 2002 Jul;64(4):673-702
12216417
Eur J Cancer. 1992;28(1):82-6
1567698
J Natl Cancer Inst. 1986 Jul;77(1):247-52
2425117
Bull Math Biol. 1998 Sep;60(5):857-99
9739618
Cytotechnology. 1998 Sep;27(1-3):95-111
19002786
J Theor Biol. 2003 Nov 21;225(2):257-74
14575659
Ann Biomed Eng. 2008 Feb;36(2):254-61
18172768
Mol Cell Biol. 1989 Aug;9(8):3284-91
2552289
Biomed Microdevices. 2004 Dec;6(4):297-309
15548877
Br J Cancer. 2005 Aug 8;93(3):302-9
16052217
J Cell Biol. 2000 Mar 6;148(5):863-70
10704438
Clin Cancer Res. 2002 Mar;8(3):878-84
11895922
J Math Biol. 2003 Mar;46(3):191-224
12728333
Biochemistry. 1989 Jan 10;28(1):274-82
2706251
Neuroimage. 2007;37 Suppl 1:S120-34
17629503
Br J Cancer. 1988 Sep;58(3):330-4
3179185
Microvasc Res. 1996 May;51(3):327-46
8992232
J Control Release. 2001 Jul 6;74(1-3):7-25
11489479
Bull Math Biol. 2005 Mar;67(2):211-59
15710180
Cancer Treat Rev. 2003 Aug;29(4):297-307
12927570
Math Biosci. 2003 Feb;181(2):177-207
12445761
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14212-7
11724924
J Math Biol. 2000 Nov;41(5):455-75
11151708
Biochim Biophys Acta. 1990 Nov 12;1055(2):117-25
2242381
Cancer Cell. 2003 Apr;3(4):347-61
12726861
Ann Thorac Surg. 2001 Oct;72(4):1173-8
11603432
J Pharmacokinet Biopharm. 1998 Dec;26(6):717-33
10485082
Nat Rev Drug Discov. 2005 Apr;4(4):307-20
15789122
Nat Rev Cancer. 2005 Mar;5(3):161-71
15738981
AAPS PharmSci. 2001;3(2):E15
11741266
Anticancer Res. 1996 Mar-Apr;16(2):741-9
8687123
Exp Cell Res. 1999 Jul 10;250(1):131-41
10388527
Nature. 2004 Feb 19;427(6976):695
14973470
Cancer Res. 1974 Oct;34(10):2814-22
4369924
Neoplasia. 2003 Mar-Apr;5(2):161-9
12659689
Biochem Pharmacol. 1998 Nov 1;56(9):1209-17
9802333
J Theor Biol. 2007 Apr 21;245(4):677-704
17239903
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8782-8
16361566
Science. 1990 Mar 23;247(4949 Pt 1):1457-61
2108497
J Theor Biol. 2006 Aug 7;241(3):564-89
16487543
Biochem Pharmacol. 1993 May 25;45(10):2079-85
8512589
Neoplasia. 2005 Jul;7(7):705-13
16026650
Biochim Biophys Acta. 1989 Sep 19;1013(2):109-17
2765536
Cancer Chemother Pharmacol. 1990;26(3):198-204
2357767
Cancer Chemother Pharmacol. 1984;12(1):59-63
6690077
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6772-9
16203763
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3497-504
7909602